Ionis Pharmaceuticals
Biotechnology company / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Ionis Pharmaceuticals?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The company has three commercially approved medicines: Spinraza (Nusinersen), Tegsedi (Inotersen), and Waylivra (Volanesorsen) and has four drugs in pivotal studies: tominersen for Huntington's disease, tofersen for SOD1-ALS, AKCEA-APO(a)-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis.[4]
This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
|
Quick Facts Formerly, Company type ...
Formerly | Isis Pharmaceuticals, Inc. |
---|---|
Company type | Public company |
| |
Industry | Biotechnology |
Founded | 1989; 35 years ago (1989) |
Founder | Stanley T. Crooke |
Headquarters | Carlsbad, California, U.S. |
Key people | Brett P. Monia (CEO)[1] Elizabeth L. Hougen (CFO)[2] Joseph Loscalzo (Chairman of the Board)[3] |
Products | nusinersen, inotersen, volanesorsen, plazomicin, mipomersen |
Revenue | US$587 million (2022) |
US$−270 million (2022) | |
Total assets | US$2.53 billion (2022) |
Total equity | US$573 million (2022) |
Number of employees | 796 (December 2022) |
Website | ionispharma |
Footnotes / references [4] |
Close
The company was named Isis Pharmaceuticals until December 2015.[5]